Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

Analyst Ratings

Truist Securities Maintains Buy Rating for Ducommun: Here’s What You Need To Know

By Benzinga Insights

January 10, 1:00 PM

Truist Securities has decided to maintain its Buy rating of Ducommun (NYSE:DCO) and raise its price target from…

DCO

5 Dividend Stocks That Promise Solid Growth

By Zacks

July 13, 10:06 AM

Heightened volatility and uncertainty in the stock market triggered by decades-high inflation, the Russia-Ukraine conflict and Fed's aggressive tightening policy have compelled investors to search for consistent income. In this regard, nothing is better than dividend investing.

ARCB